Creech R H, Stanley K, Vogl S E, Ettinger D S, Bonomi P D, Salazar O
Cancer Treat Rep. 1982 Jun;66(6):1417-9.
Seventy-three patients with small cell lung carcinoma refractory to standard chemotherapy were entered in this phase II randomized study of cisplatin, maytansine, and chlorozotocin. Of the 58 evaluable patients, only one partial response was observed among 21 patients given cisplatin, and no responses were seen among 19 given maytansine or 18 given chlorozotocin. One patient treated with chlorozotocin and two treated with cisplatin experienced life-threatening thrombocytopenia. One third of the maytansine-treated patients experienced moderate or severe neurologic toxicity. The overall median survival was 9.7 weeks. Chlorozotocin treatment was associated with inferior survival (7.7 weeks).
73例对标准化疗耐药的小细胞肺癌患者进入了这项关于顺铂、美登素和氯脲霉素的II期随机研究。在58例可评估患者中，接受顺铂治疗的21例患者仅观察到1例部分缓解，接受美登素治疗的19例患者和接受氯脲霉素治疗的18例患者均未出现缓解。1例接受氯脲霉素治疗的患者和2例接受顺铂治疗的患者出现了危及生命的血小板减少症。三分之一接受美登素治疗的患者出现了中度或重度神经毒性。总体中位生存期为9.7周。氯脲霉素治疗与较差的生存期（7.7周）相关。
